📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
10 articles
AVG GRADE
NEUTRAL
score: 0.35
SENTIMENT
NEUTRAL
TOTAL VIEWS
19
ERAS Stock Analysis & AI Grade: NEUTRAL
10 articles analyzed · Sentiment: NEUTRAL · AI-powered equity research
RECENT COVERAGE · 10 ARTICLES
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Erasca, Inc. (ERAS) faces a class action lawsuit with an August 10, 2026 application deadline, as announced by law firm Kahn Swick &...
Kaplan Fox Reminds Erasca, Inc. (ERAS) Investors Seeking Recovery of the Lead Plaintiff Deadline on August 10, 2026
Erasca Inc. (ERAS) faces class action litigation with a lead plaintiff deadline of August 10, 2026. This announcement reflects potential...
Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS)
Erasca (ERAS) has emerged as a potential competitor to Revolution Medicines' daroxonrasib with its ERAS-0015 candidate, positioning...
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
ERAS completed an upsized equity offering of 36.1 million shares at $17.50 per share, raising approximately $632.5 million in gross...
Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results
Erasca (ERAS) posted a substantial single-day gain of 8.9% following disclosure of positive clinical trial outcomes for its RAS-mutant...
Erasca Announces Pricing of Upsized Public Offering of Common Stock
Erasca (ERAS), a clinical-stage precision oncology company, announced the pricing of an upsized public offering at $17.50 per share,...
Erasca announces $500M common stock offering (ERAS:NASDAQ)
Erasca announced a $500M common stock offering with a $75M greenshoe option, raising capital for R&D and operational needs. This...
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
Erasca (ERAS), a clinical-stage precision oncology company, announced a $500 million public offering of common stock with an additional...
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Erasca has released updated Phase 1 clinical trial data for ERAS-0015, a pan-RAS molecular glue candidate targeting KRAS-mutant solid...
ERAS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Erasca (ERAS) faces an August 10, 2026 deadline for investors to join an ongoing securities class action lawsuit, signaling continued...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice